The drug approval crisis facing gene therapy; Medicare sidesteps Alzheimer's drug prices

Taking stock of the drug industry, from the lab to the medicine chest

July 31, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Molly Ferguson for STAT STAT+ | Gene therapy is in crisis. For nine hours, the field's leading minds looked for a solution With the field struggling, top scientists searched for a way to bring gene therapy to the millions of rare disease patients. By Jason Mast STAT+ | Sage hopes for a blockbuster in fast-acting antidepressant now before FDA The antidepressant, called zuranolone, is designed to kick in within the first three days of treatment and be stopped after 14 days. By Brittany Trang Vivek Ramaswamy wants to 'gut' the FDA. His claims don't hold up to scrutiny Vivek Ramaswamy, the former biotech exec and current presidential candidate, has thoughts on the FDA. They don't all hold up to scrutiny. By Adam Feuerstein and Matthew Herper Adobe STAT+ | New safety details link Apellis eye drug to rare cases of blindness. Cause still unknown The new safety information was presented by a committee of eye disease experts at a meeting of the American Society of Retinal Specialists. By Adam Feuerstein Opinion: New attacks on the drug industry would have made my breakthrough sickle cell treatment impossible I fear that as a direct result of two recent policy shifts, success stories like mine will become impossible. By Ted W. Love STAT+ | Medicare wants to improve Alzheimer's care, but sidesteps drug prices Medicare pilot aims to improve dementia care and reduce stress on unpaid caregivers, but it sidesteps Alzheimer's drug costs. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser